Frost & Sullivan releases the 'Blue Book on the Digital and Intelligent Development of China's Pharmaceutical Industry 2023' (with full text available for download)

Against the backdrop of rapid development in modern manufacturing and cross-integration and innovation of emerging technologies, the Fourth Industrial Revolution, characterized by the creation of smart factories using information integration and control systems to achieve digital and intelligent manufacturing, has arrived. It has rapidly triggered a new round of industrial transformation competition globally.

Source: Analysis by Frost & Sullivan

Industry 4.0 is centered around 'intelligence + networking', taking the information physical system as its key point. It achieves a new generation of production methods that are intelligent and standardized through dynamic resource allocation, realizing real-time monitoring, flexible regulation, automatic processing, and other intelligent production activities based on the collection, transmission, processing, and analysis of large amounts of data. 'Intelligence' is the biggest feature of Industry 4.0, which enables real-time monitoring, flexible control, and automatic processing through intelligent production activities based on the collection, transmission, processing, and analysis of massive data.

The digitalization of the pharmaceutical industry refers to the use of new-generation digital intelligence technologies to build a digital ecosystem platform for the entire industrial chain of pharmaceutical enterprises, reshaping business processes and enhancing the core competitiveness of enterprises. In terms of business coverage, the digitalization of the pharmaceutical industry is not just about empowering the drug production process with digital intelligence; it should cover the entire life cycle of drugs and the entire industrial chain, including drug research and development, production, sales, and use. It encompasses upstream raw materials, downstream users, as well as CXO service providers, constructing a fully connected, efficient, controllable, and environmentally friendly pharmaceutical scenario that is all-scenario, fully perceptual, fully interconnected, and fully digitalized.

The pharmaceutical industry is characterized by high investment, high output, high risk, long cycle, and technological intensity. Comprehensively advancing the digital and intelligent transformation of the pharmaceutical industry can help pharmaceutical enterprises achieve efficient research and development, safe production, and compliant operations. It is the only way for pharmaceutical enterprises to achieve sustainable development. The 'Blue Book' expounds on the inevitability of the digital and intelligent transformation of the pharmaceutical industry and provides a detailed analysis of strategic opportunities for transformation from the dimensions of 'quality improvement', 'efficiency enhancement', and 'innovation'.

Manufacturing is a pillar industry of China's national economy and the leading sector for economic growth. After years of development, China's manufacturing industry has shown a situation of 'big but not strong'. Following Germany's release of 'Industry 4.0' in 2013, the Chinese government introduced 'Made in China 2025' in 2015, proposing a ten-year development plan for manufacturing for the first time, with goals directly aimed at 'Chinese creation' and 'manufacturing power'. The report of the 20th National Congress of the Communist Party of China pointed out that 'we should focus on developing the real economy, promote new industrialization, and accelerate the construction of manufacturing power, quality power, aerospace power, transportation power, cyber power, and digital China'. Digital intelligence, as an important means to enhance the innovation capabilities of manufacturing, promote high-quality industrial development, and sustainable economic development, is an important way to transform 'Made in China' into 'Chinese creation'.

From a top-level design perspective, our country has introduced several outline policies to promote the digital and intelligent development of the pharmaceutical industry. In addition, multiple policies have been introduced with the aim of achieving full-chain supervision from laboratory research and development to end-user use by promoting the digital and intelligent transformation of the pharmaceutical industry. This will enhance the innovation, quality, and efficiency of drugs in our country and drive the sustainable development of the pharmaceutical industry. The 'Blue Book' details the content of these relevant policies.

With the deepening of global pharmaceutical collaborative development, China's position in the global biopharmaceutical market is becoming increasingly important. China firmly holds the first place in raw material drug production and exports, becoming the second-largest pharmaceutical market after the United States, accounting for about one-fifth of the global market share. Among them, the growth of the patent drug market is particularly notable, with its proportion continuously increasing, reaching about twice that of generic drugs & biosimilars in 2022.

Source: Analysis by Frost & Sullivan

In the future, expanding international business will inevitably become an important strategic decision for pharmaceutical companies in our country. Focusing on global market demands, China's pharmaceutical industry will provide high-quality products, accurately predict product demand in different regions, use more efficient logistics services, achieve better customer maintenance services, and implement refined management. Meanwhile, digital intelligence technology has become a necessary means for pharmaceutical companies to enter the international market.

Against the backdrop of rapid growth in China's innovative drug R&D pipeline, there is an increasingly acute issue of involution. How to improve the success rate of drug R&D, shorten the time required for R&D, optimize drug efficacy, etc., has become a focal point of concern for many pharmaceutical companies today. Digital intelligence technology can improve R&D efficiency and success rates, reduce corporate costs, and help enterprises break through barriers. The steady progress of centralized drug procurement will continue to expand the scope and proportion of procurement amounts, squeezing the profit margins of generic drugs and prompting generic drug companies to explore more efficient and lower-cost production models; on the other hand, volume-based procurement will force enterprises to specialize in R&D and innovation drugs. And how to carry out drug R&D and production efficiently has become an issue that pharmaceutical companies must face squarely. The application of digital intelligence technology helps enterprises improve their innovative R&D capabilities and production efficiency, and cope with the deepening trend of centralized procurement by reducing costs and increasing efficiency.In addition, the 'Blue Book' analyzes the driving factors for the digital and intelligent development of the pharmaceutical industry from multiple dimensions.

New drug research and development face challenges such as long R&D cycles, high costs, and low success rates. Biotechnology Innovation Organization data shows that the development of new molecular entities typically takes about 10-15 years, with R&D costs reaching up to $500 million to $1 billion. The success rates of various drugs at different stages also vary, and the success rate of innovative drugs is lower than that of non-patented drugs.

Source: Analysis by Frost & Sullivan

Source: Analysis by Frost & Sullivan

The achievements and evolution of pharmaceutical enterprises in digital transformation are mainly evaluated and measured through the following two dimensions: horizontal and vertical. In terms of vertical intelligent upgrade, the first level is the digital phase, which is a process of transforming physical world information into computer data based on data. When the system progresses to the automation phase, tasks such as data collection, analysis, and result display by business units are handed over to machines or programs. In the intelligent phase, the system will further possess capabilities of state perception, real-time analysis, scientific decision-making, and precise execution. In terms of business application scope, initially focusing on single-point businesses, the application of digital technologies has gradually expanded outward, achieving a synergistic effect that connects upstream and downstream businesses in the chain. Eventually, the entire business chain is included in the upgrade scope, forming a deeply integrated digital ecosystem.

Source: Analysis by Frost & Sullivan

Technical capabilities and willingness to act are complementary, constituting the foundational elements required for successful implementation of transformation strategies. Based on an analysis of these two key elements, the digital and intelligent transformation of the pharmaceutical industry faces challenges such as insufficient data foundation, lagging technical capabilities, lack of overall awareness, outdated management organizational forms, talent culture dilemmas within enterprises, and immense regulatory pressure.The 'Blue Book' identifies four major challenges: 'Consolidating the Foundation', 'Unity of Knowledge and Action', 'Long-Termism', and 'Seeking Change While Stabilizing'. It provides a systematic analysis of the main common issues at this stage as well as countermeasures.

The digital and intelligent transformation is a vast and complex systematic project.The Blue Book describes the implementation path of digital transformation, from cognition, planning, implementation to evaluation:

1) Value Proposition, with a Mission First Approach:Clarifying goals and visions, which are consistent with the company's core business and long-term development plans, helps to determine the direction and focus of digital transformation.

2) Assess current status and requirements:Comprehensively assess the existing digital capabilities. At the same time, based on weaknesses and deficiencies, clarify business needs, determine priority areas and key issues for digital transformation, and avoid blind trial-and-error and resource waste.

3) Develop a digital and intelligent strategic plan:Plan and clarify the time schedule, scope, key areas of transformation, and investment budget. It is recommended to adopt a platform-based technical architecture to reduce system silos and improve development efficiency. Set differentiated strategic plans according to different strategic needs, business structures, and characteristics of sub-industries, and select appropriate reform paths and transformation routes.

4) Construction facilities and technology introduction:Enterprises need to introduce a series of advanced digital and intelligent technologies, and build robust data storage and management systems, including data warehouses, data security and privacy protection mechanisms, etc.

5) Step-by-step implementation, with full-scale rolloutSelect priority transformation areas that are closely aligned with the long-term strategy and core business, allowing enterprises to proceed step by step. Verify the feasibility of technologies and solutions through small-scale pilots, collect feedback, and then gradually expand the scale by introducing more business processes and systems.

6) Continuous improvement and optimization:By identifying priority transformation areas that are closely aligned with long-term strategy and core business, enterprises can proceed step by step. In small-scale pilots, the feasibility of technologies and solutions is verified, feedback is collected, and then the scale is gradually expanded to introduce more business processes and systems.

Source: Analysis by Frost & Sullivan

In addition, talent, technology, and capital are the cornerstones of the construction of a digital intelligence system. The 'Blue Book' analyzes the importance of these three core elements: talent, technology, and capital, while also sorting out measures and suggestions for industry participants such as governments, enterprises, and industry associations to enhance their core development elements.

Looking globally, governments around the world have recognized the positive role of digital and intelligent transformation in the development of manufacturing and have formulated national industrial modernization development strategies, such as Germany's 'Industry 4.0', the United States' 'Industrial Internet', as well as the UK's 'Digital Strategy' and South Korea's 'Basic Plan for the Internet of Things'. Governments guide market entities onto the path of digital and intelligent transformation, aiming to enhance the competitiveness of traditional industries through this path. Among them, the digital and intelligent development of the pharmaceutical industry is one of the important breakthroughs in the development of the digital economy.The 'Blue Book' further sorts out the relevant policy measures of countries such as the United States, South Korea, Russia, and Singapore in supporting the digital and intelligent transformation of the pharmaceutical industry.

Digital intelligence upgrade is an important component of the strategic planning of multinational pharmaceutical companies. Advanced large multinational pharmaceutical companies actively embrace the wave of digital intelligence, deeply deploying in digital intelligent innovation and development. They have achieved relatively outstanding results in processes such as drug research and development, production, distribution, and management, and have entered a highly mature stage of large-scale digitization.The digital and intelligent development of China's pharmaceutical industry is in a process of exploration, gradual progress, and continuous improvement. The 'Blue Book' starts from representative application scenarios such as digital and intelligent R&D, production, and logistics, and sorts out the practical experience and application achievements made by multinational pharmaceutical companies in recent years, aiming to provide some references for Chinese pharmaceutical companies to consolidate their own development paths.

Some domestic pharmaceutical companies have achieved excellent results in scenarios such as product research and development, process development and optimization, factory design, production operations, warehousing and distribution, quality control, etc., successfully setting benchmarks for digital and intelligent application scenarios. At the same time, to meet the diverse transformation needs of pharmaceutical companies, digital and intelligent technology service providers offer efficient, professional, and secure digital and intelligent solutions for the pharmaceutical industry, build a global collaborative technical system and intelligent platform, and work hand in hand with pharmaceutical companies to construct a healthy digital and intelligent ecosystem.

The 'Blue Book' presents the layout, application status quo, and practical achievements of digital intelligence development by some domestic pharmaceutical companies. It also sorts out the digital intelligence service content, technical advantages, and practical cases provided by some domestic digital intelligence service providers.